Etoricoxib for Costochondritis
Rationale for Use in Costochondritis
- Etoricoxib can be used effectively for costochondritis as a COX-2 selective NSAID for pain and inflammation control, but should be limited to short-term use (2-4 weeks maximum) at the lowest effective dose due to cardiovascular and gastrointestinal risks 1
Recommended Treatment Approach
- Start with 60 mg once daily, the standard dose for musculoskeletal conditions, rather than the 90 mg dose used for rheumatoid arthritis 2
- Limit treatment duration to 2-4 weeks for the active inflammatory phase, then reassess response 1
- Consider switching to on-demand treatment if symptoms persist beyond initial treatment period rather than continuous daily dosing 1
Pre-Treatment Risk Assessment
- Evaluate cardiovascular risk factors, particularly uncontrolled hypertension, as COX-2 selectivity increases thrombotic cardiovascular event risk proportional to baseline patient risk 1
- Consider gastrointestinal history, including prior ulcers or bleeding, though etoricoxib has superior GI safety compared to non-selective NSAIDs 2
- Evaluate renal function, especially in elderly patients, as etoricoxib should not be used with eGFR <30 ml/min 3
Safety Considerations and Monitoring
- For patients with known cardiovascular disease or high-risk factors, consider alternative pain management first, such as acetaminophen, tramadol, or topical NSAIDs, before using etoricoxib 1
- The American Heart Association cautions against assuming etoricoxib is as safe as traditional NSAIDs in cardiovascular disease patients 1
- Monitor blood pressure during treatment, as hypertension and edema are common side effects 1
- Co-prescribe a proton pump inhibitor for gastroprotection if using etoricoxib, particularly in patients with GI risk factors 2
Alternative Considerations
- Topical NSAIDs may be considered for localized chest wall pain, though evidence is limited for costochondritis specifically 2
- Acetaminophen as first-line for patients with cardiovascular contraindications 1
- Local corticosteroid injections at costochondral junctions for refractory cases, extrapolating from evidence in other musculoskeletal conditions 4
Contraindications for Etoricoxib
Absolute Contraindications
- Etoricoxib is absolutely contraindicated in patients with established ischemic heart disease or cerebrovascular disease, as it increases the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal 5
- The American College of Cardiology implies that etoricoxib is contraindicated in patients with perioperative pain in the setting of coronary artery bypass graft (CABG) surgery, as it is an FDA black box contraindication applicable to all NSAIDs including etoricoxib 5
- Etoricoxib is contraindicated in patients with active peptic ulcer disease, as NSAIDs including etoricoxib cause increased risk of serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach or intestines 5, 6
- Current active gastrointestinal bleeding represents an absolute contraindication to all NSAIDs, including etoricoxib 6
- Etoricoxib should not be used in patients with severe renal impairment (eGFR <30 mL/min), as it can worsen renal function 6
- Severe hepatic impairment or active liver failure is an absolute contraindication for etoricoxib, as its AUC increases by approximately 40% in patients with moderate hepatic impairment 6
- Known hypersensitivity to etoricoxib or any component of the formulation is a contraindication for its use 5
Relative Contraindications
- Elderly patients are at greater risk for serious gastrointestinal and renal events when taking etoricoxib, and should be monitored closely 5
- Patients with a history of peptic ulcer disease (even if healed) should be co-prescribed a proton pump inhibitor when taking etoricoxib, as it increases the risk of gastrointestinal bleeding 6
- Concomitant use of corticosteroids or SSRIs with etoricoxib increases gastrointestinal bleeding risk, and should be avoided if possible 6
- Helicobacter pylori infection increases gastrointestinal risk when taking etoricoxib, and should be treated before initiating therapy 6